

Pembrolizumab PEARLS/KEYNOTE-091

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Not qualified for an ESMO-MCBS credit



#### Serious and disabling adverse effects



#### Other adjustments



Pembrolizumab PEARLS/KEYNOTE-091

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy

Experimental Arm: Pembrolizumab

Control Arm: Placebo



